Pharmacogenomics¶
Chapter 72 | Pharmacogenomics and Genetic Variation in Drug Response
KEY CLINICAL POINTS¶
- Genetic variants significantly influence drug metabolism, efficacy, and toxicity (e.g., CYP2D6, CYP2C19, VKORC1).
- Pharmacogenomic testing guides dosing adjustments (e.g., warfarin, clopidogrel) and avoids adverse drug reactions (ADRs).
- HLA alleles (e.g., HLA-B57:01, HLA-B15:02) are critical for predicting drug hypersensitivity (e.g., abacavir, carbamazepine).
- Transporter variants (e.g., SLCO1B1) affect drug uptake and toxicity (e.g., simvastatin-induced myopathy).
- Pharmacogenomics integrates genomic data with clinical decision support systems (CDSS) for personalized medicine.
1. DEFINITION & OVERVIEW¶
Pharmacogenomics is the study of how genetic variation influences drug response, encompassing pharmacokinetics (drug metabolism) and pharmacodynamics (drug-target interactions). It integrates genomic data with clinical practice to optimize drug therapy and avoid adverse effects.
Table e72-1: Genetic Variants and Drug-Related Phenotypes¶
| Genetic Variant | Drug | Effect | Population |
|---|---|---|---|
| CYP2D6 PM | Codeine | Blunted analgesia | European/African |
| CYP2C19 PM | Clopidogrel | Reduced antiplatelet effect | Asian (20%) |
| VKORC1 | Warfarin | Increased bleeding risk | European/African |
| DPYD | 5-Fluorouracil | Severe toxicity | East Asian |
| TPMT | 6-Mercaptopurine | Severe myelosuppression | European/African |
Table e72-2: Pharmacogenetic Variants Affecting Drug Response¶
| Gene | Variant Type | Clinical Impact | Example Drug |
|---|---|---|---|
| CYP2D6 | Loss-of-function | Altered drug metabolism | Codeine, Tamoxifen |
| CYP2C19 | Loss-of-function | Reduced drug efficacy | Clopidogrel |
| VKORC1 | Promoter polymorphism | Warfarin sensitivity | Warfarin |
| SLCO1B1 | SNP | Simvastatin toxicity | Simvastatin |
| HLA-B | Allele | Drug hypersensitivity | Abacavir, Carbamazepine |
1.1 Genetic Variation and Drug Response¶
Single nucleotide polymorphisms (SNPs), copy number variations, and promoter polymorphisms modulate drug metabolism, transport, and target interactions. These variants can alter drug efficacy, toxicity, and dosing requirements.
1.2 Clinical Relevance¶
Pharmacogenomics enables personalized medicine by identifying genetic markers linked to drug response (e.g., CYP2D6 polymorphisms affecting codeine metabolism) and adverse reactions (e.g., HLA-B*57:01 and abacavir hypersensitivity).
2. EPIDEMIOLOGY¶
Genetic variation in drug metabolism and response varies by ancestry. For example, CYP2C19 PM phenotype occurs in 20% of Asians vs. 2-3% in other populations. HLA alleles associated with drug hypersensitivity (e.g., HLA-B*57:01) are more common in certain ethnic groups.
2.1 Ancestry and Variant Frequency¶
CYP2D6 PM phenotype: 5-10% in European/African populations, rare in Asians. VKORC1 variants: higher frequency in European/African populations, affecting warfarin dosing requirements.
2.2 Risk Factors¶
Genetic variants (e.g., CYP2C19 PM, HLA-B*57:01) increase risk of ADRs (e.g., clopidogrel resistance, abacavir hypersensitivity). Ethnicity and family history influence variant prevalence.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Genetic variants alter drug metabolism, transport, and target interactions. For example, CYP2D6 polymorphisms affect codeine metabolism, while HLA alleles mediate immune responses to drugs like abacavir.
3.1 Drug Metabolism¶
CYP2D6 and CYP2C19 variants modulate drug clearance (e.g., codeine to morphine, clopidogrel activation). VKORC1 variants affect vitamin K metabolism, influencing warfarin sensitivity.
4. CLINICAL FEATURES¶
Pharmacogenomic variants cause variable drug responses, including reduced efficacy (e.g., CYP2C19 PM with clopidogrel) or increased toxicity (e.g., DPYD variants with 5-FU). Adverse effects may include myopathy, bleeding, or hypersensitivity reactions.
4.1 Drug-Induced Toxicity¶
Simvastatin toxicity (SLCO1B1 variants), 5-FU toxicity (DPYD variants), and warfarin-induced bleeding (VKORC1 variants) are well-documented pharmacogenomic risks.
4.2 Drug Efficacy Variability¶
CYP2C19 PM phenotype reduces clopidogrel efficacy, while CYP2D6 UM phenotype enhances codeine metabolism. HLA-B*57:01 carriers may experience abacavir-induced hypersensitivity.
5. DIFFERENTIAL DIAGNOSIS¶
Pharmacogenomic variants must be differentiated from other causes of drug response variability, such as comorbidities, drug interactions, or environmental factors. For example, CYP2C19 PM phenotype must be distinguished from acquired drug resistance.
5.1 Drug Hypersensitivity¶
HLA-B57:01-associated abacavir hypersensitivity vs. other drug allergies. HLA-B15:02 and carbamazepine-induced Stevens-Johnson syndrome (SJS/TEN).
5.2 Drug Efficacy¶
CYP2C19 PM phenotype (clopidogrel resistance) vs. other causes of antiplatelet failure (e.g., uremia, aspirin resistance).
6. INVESTIGATIONS & DIAGNOSIS¶
Pharmacogenetic testing (e.g., CYP2C19, HLA-B typing) identifies variants linked to drug response. Genetic assays (SNP arrays, sequencing) and clinical algorithms (e.g., warfarin dosing algorithms) guide diagnosis.
6.1 Diagnostic Testing¶
Genotyping for CYP2C19, CYP2D6, VKORC1, and HLA alleles. N-acetyltransferase (NAT1/NAT2) testing for drug-induced lupus (procainamide/hydralazine).
6.2 Algorithms¶
Warfarin dosing algorithms incorporating CYP2C9, VKORC1, and clinical factors. Platelet function testing for clopidogrel responders (CYP2C19 genotype).
7. MANAGEMENT & TREATMENT¶
Pharmacogenomic-guided dosing (e.g., warfarin, clopidogrel) and drug selection (e.g., avoiding carbamazepine in HLA-B*15:02 carriers) optimize therapy. Alternative therapies (e.g., ticagrelor for CYP2C19 PM) reduce ADR risk.
7.1 Dosing Adjustments¶
Warfarin: CYP2C9/VKORC1-guided dosing. Clopidogrel: avoid in CYP2C19 PM patients; use ticagrelor/prasugrel instead.
7.2 Drug Selection¶
Avoid abacavir in HLA-B57:01 carriers. Use alternative anticonvulsants (e.g., lamotrigine) in HLA-B15:02 carriers.
8. PROGNOSIS & COMPLICATIONS¶
Pharmacogenomic variants may lead to severe ADRs (e.g., malignant hyperthermia, drug-induced liver injury) or reduced therapeutic efficacy. Early detection via testing prevents complications.
8.1 Adverse Outcomes¶
5-FU toxicity (DPYD variants), abacavir hypersensitivity (HLA-B*57:01), and simvastatin-induced myopathy (SLCO1B1 variants).
8.2 Long-Term Risks¶
Warfarin-induced bleeding (VKORC1 variants), clopidogrel resistance (CYP2C19 PM), and drug-induced liver injury (e.g., flucloxacillin).
9. SPECIAL CONSIDERATIONS¶
Pharmacogenomics in pregnancy, pediatrics, and elderly populations requires careful dosing adjustments. For example, warfarin dosing in pregnancy must account for VKORC1/CYP2C9 variants.
9.1 Pregnancy¶
Warfarin dosing adjustments based on CYP2C9/VKORC1 variants. Avoid certain drugs (e.g., carbamazepine) in HLA-B*15:02 carriers.
9.2 Pediatrics¶
Avoid codeine in children due to CYP2D6 PM risk. Use alternative analgesics (e.g., tramadol) in pediatric patients.
10. KEY POINTS & CLINICAL PEARLS¶
Pharmacogenomics integrates genetic data with clinical practice to optimize drug therapy. Key pearls include: (1) Use CYP2D6/CYP2C19 testing for clopidogrel and codeine; (2) Avoid abacavir in HLA-B*57:01 carriers; (3) Adjust warfarin dosing based on CYP2C9/VKORC1 variants; (4) Use alternative therapies for CYP2C19 PM patients; (5) Implement pharmacogenetic testing via EHR systems for personalized medicine.